Public release of the Half-Year Financial Report at 30 June 2024.

See more here:
Virbac : Public release of the Half-Year Financial Report at 30 June 2024.

Please find attached 2024 Half-yearly financial report of Virbac

Read more from the original source:
Virbac : Half-yearly financial report 2024

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP

See original here:
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on September 12, 2024, the Company received a staff determination letter (the “Determination Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had not regained compliance with the Market Value of Listed Securities (“MVLS”) Requirement and the Market Value of Publicly Held Shares (“MVPHS”) requirement by September 9, 2024.

The rest is here:
Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

MARKHAM, Ontario, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Dr. Pardeep Nijhawan (“Dr. Nijhawan”) announces that as a result of grants of restricted share units (“RSUs”) of Edesa Biotech, Inc. (“Edesa”), when combined with a series of transactions (the “Transactions”) that have occurred since the date of the most recent early warning report filed by Dr. Nijhawan on November 18, 2022 (the “Previous Report”), Dr. Nijhawan has acquired “beneficial ownership” of common shares in the capital of Edesa (“Common Shares”) in an amount equal to more than 2% of the issued and outstanding Common Shares since the date of the Previous Report.

Read the rest here:
Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.

MORRISTOWN, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- The Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and Drug Administration (FDA) met today to discuss Intercept’s supplemental New Drug Application (sNDA) for OCALIVA® (obeticholic acid, OCA) for the treatment of primary biliary cholangitis (PBC) – a rare, progressive disease that disproportionally affects women. The sNDA was submitted to support full approval of OCALIVA and to satisfy post-marketing requirements confirming a clinical benefit in patients with PBC.

Read this article:
Company Statement on FDA Advisory Committee Meeting  

- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose- >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy- Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations- GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting- iTeos to host a conference call on Monday, September 16, 2024 at 8:00am ET

More:
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of...

-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort ---- No New Safety Signals or Added Systemic Safety Concerns Observed --

Read the rest here:
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

Giralt on MDS Transplant Timing and Candidacy  Targeted Oncology

Visit link:
Giralt on MDS Transplant Timing and Candidacy - Targeted Oncology

Aging is associated with functional and molecular changes in distinct hematopoietic stem cell subsets  Nature.com

See the rest here:
Aging is associated with functional and molecular changes in distinct hematopoietic stem cell subsets - Nature.com

A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT)  Nature.com

More:
A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and...

ISU researcher blown away by blood cell replication discovery  Radio Iowa

Read the rest here:
ISU researcher blown away by blood cell replication discovery - Radio Iowa

Pausing biological clock could give boost to lab-produced blood stem cells  Phys.org

More here:
Pausing biological clock could give boost to lab-produced blood stem cells - Phys.org

9-year-old gets successful bone marrow transplant  The Times of India

Read more from the original source:
9-year-old gets successful bone marrow transplant - The Times of India

Dr. Crandall: Stem Cell Treatment Heals the Heart  Newsmax

Link:
Dr. Crandall: Stem Cell Treatment Heals the Heart - Newsmax

Company announcement – No. 42 / 2024

Follow this link:
Total number of shares and voting rights in Zealand Pharma on August 30, 2024

- Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue without modifications- No new safety signals observed at interim analysis- Primary endpoint of progression free survival projected to be reached in the first half of 2025

Continue reading here:
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with...

All dollar amounts reflected in Canadian dollars unless otherwise stated.

Go here to see the original:
Rakovina Therapeutics Announces 2024 Q2 Financial Results and Provides Corporate Update

August 30, 2024

Read the rest here:
Receipt of Nasdaq Delisting Determination - Plans to Appeal

Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline treatment for newly diagnosed AML patients Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline treatment for newly diagnosed AML patients

Read the original:
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop...